← Leaderboards
Andrew Justin Bryant
University Of Florida
$4,040,313
Attributed
$4,040,313
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $762.5K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,040,313 · 3
By mechanism
R01$3,783,633 · 2
K08$256,680 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Yunchao Su$4,504,620
- C Keith Ozaki$4,115,723
- Joe G. N. Garcia$45,532,409
- Anatoly E Martynyuk$5,147,863
- Arthur J. Pope$54,248
Others in their field
Other Emerging Leaders on “Pathogenesis”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,703,204
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Kathleen Maletic Neuzil · Emory University$26,258,144
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Thomas Denny · Duke University$22,999,550
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$17,335,818
Research focus
PathogenesisTransgenic MiceMonocyteMyeloid-Derived Suppressor CellsPublic HealthPulmonary HypertensionMalignant NeoplasmsMissionMorphologyMyeloid CellsImmunoregulationPhenotypeInnovationPulmonary FibrosisBleomycinLungHypoxiaMediatingImmuneIdiopathic Pulmonary FibrosisChronic Lung DiseaseMyelogenousCellsUnited States National Institutes Of Health
Grant awards (12)
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension$381,250
R01 · FY2024 · HL · contact PI
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling$381,250
R01 · FY2023 · HL · contact PI
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension$381,250
R01 · FY2023 · HL · contact PI
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension$381,250
R01 · FY2022 · HL · contact PI
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling$372,971
R01 · FY2022 · HL · contact PI
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension$381,250
R01 · FY2021 · HL · contact PI
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling$373,724
R01 · FY2021 · HL · contact PI
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension$381,250
R01 · FY2020 · HL · contact PI
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling$374,408
R01 · FY2020 · HL · contact PI
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling$375,030
R01 · FY2019 · HL · contact PI
Role of myeloid-derived suppressor cells in pulmonary hypertension associated with pulmonary fibrosis$105,000
K08 · FY2019 · HL · contact PI
Role of myeloid-derived suppressor cells in pulmonary hypertension associated with pulmonary fibrosis$151,680
K08 · FY2018 · HL · contact PI